What is Pacira Pharmaceuticals, Inc. share price today?

Pacira Pharmaceuticals, Inc. (PCRX) share price today is {{live_price}}.

Can Indians buy Pacira Pharmaceuticals, Inc. shares?

Yes, Indians can invest in the Pacira Pharmaceuticals, Inc. (PCRX) from India. With INDmoney, you can buy Pacira Pharmaceuticals, Inc. at 0 brokerage. The step-by-step process is as follows: Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes) Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates. Once funds are transferred successfully, you can buy Pacira Pharmaceuticals, Inc. at zero transaction cost.

How can I buy Pacira Pharmaceuticals, Inc. shares from India?

It is very easy to buy Pacira Pharmaceuticals, Inc. from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Pacira Pharmaceuticals, Inc. be purchased?

Yes, you can buy fractional shares of Pacira Pharmaceuticals, Inc. with INDmoney app.

What are the documents required to start investing in Pacira Pharmaceuticals, Inc. stocks?

To start investing in Pacira Pharmaceuticals, Inc., You will need the following documents: Proof of Identification (PAN, Aadhaar etc) Proof of address (Aadhaar, Voter ID etc) These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Pacira Pharmaceuticals, Inc.

Today’s highest price of Pacira Pharmaceuticals, Inc. (PCRX) is {{1_rba_end}}. Today’s lowest price of Pacira Pharmaceuticals, Inc. (PCRX) is {{1_rba_st}}.

What is today's market capitalisation of Pacira Pharmaceuticals, Inc.

Today's market capitalisation of Pacira Pharmaceuticals, Inc. PCRX is 806.8M

What is the 52 Week High and Low Range of Pacira Pharmaceuticals, Inc.

52 Week High {{rba_end}} 52 Week Low {{rba_st}}

How much percentage Pacira Pharmaceuticals, Inc. is down from its 52 Week High?

Pacira Pharmaceuticals, Inc. (PCRX) share price is {{live_price}}. It is down by {{w52lu}}% from its 52 Week High price of {{rba_end}}.

How much percentage Pacira Pharmaceuticals, Inc. is up from its 52 Week low?

Pacira Pharmaceuticals, Inc. (PCRX) share price is {{live_price}}. It is up by {{w52hd}}% from its 52 Week Low price of {{rba_st}}.

What are the historical returns of Pacira Pharmaceuticals, Inc.?

1 Month Returns {{1mr}}% 3 Months Returns {{3mr}}% 1 Year Returns {{1yr}}% 5 Years Returns {{5yr}}%

Who is the Chief Executive Officer (CEO) of Pacira Pharmaceuticals, Inc.

Mr. Daryl Gaugler is the current Chief Executive Officer (CEO) of Pacira Pharmaceuticals, Inc..

Home>
US Stocks>
Pacira Pharmaceuticals, Inc.

Pacira Pharmaceuticals, Inc. (PCRX)

$17.18

-0.31

(-1.77%)▲

Live

Performance

$17.00
$17.56
$17.18
1.04%
Downside
Day's Volatility :3.18%
Upside
2.16%
$11.16
$35.95
$17.18
35.02%
Downside
52 Weeks Volatility :68.95%
Upside
52.21%

Returns

Period	Pacira Pharmaceuticals, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	-13.46%	3.6%	0.0%
6 Months	-32.99%	10.2%	0.0%
1 Year	-37.56%	19.6%	0.0%
3 Years	-67.07%	16.8%	-23.0%

Highlights

Market Capitalization	806.8M
Book Value	$19.07
Earnings Per Share (EPS)	1.34
PE Ratio	13.05
PEG Ratio	-3.83
Wall Street Target Price	24.25

Profit Margin	9.21%
Operating Margin TTM	17.4%

Return On Assets TTM	3.96%
Return On Equity TTM	7.54%

Revenue TTM	690.3M
Revenue Per Share TTM	14.88
Quarterly Revenue Growth YOY	5.0%
Gross Profit TTM	393.2M
EBITDA	175.3M
Diluted Eps TTM	1.34
Quarterly Earnings Growth YOY	-0.24

EPS Estimate Current Year	3.04
EPS Estimate Next Year	3.27
EPS Estimate Current Quarter	0.7
EPS Estimate Next Quarter	0.68

Analyst Recommendation

Buy

93%Buy

6%Hold

0%Sell

Based on 16 Wall street analysts offering stock ratings for Pacira Pharmaceuticals, Inc.(by analysts ranked 0 to 5 stars)

Based on 16 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast

What analysts predicted

Upside of 41.15%

Current $17.18

Target $24.25

Company Financials

	FY18	Y/Y Change
Revenue	337.3M	↑ 17.67%
Net Income	-471.0K	↓ 98.89%
Net Profit Margin	-0.14%	↑ 14.73%

	FY19	Y/Y Change
Revenue	421.0M	↑ 24.83%
Net Income	-11.0M	↑ 2238.85%
Net Profit Margin	-2.62%	↓ 2.48%

	FY20	Y/Y Change
Revenue	420.8M	↓ 0.05%
Net Income	145.5M	↓ 1421.01%
Net Profit Margin	34.58%	↑ 37.2%

	FY21	Y/Y Change
Revenue	541.5M	↑ 28.68%
Net Income	42.0M	↓ 71.15%
Net Profit Margin	7.75%	↓ 26.83%

	FY22	Y/Y Change
Revenue	666.8M	↑ 23.14%
Net Income	15.9M	↓ 62.1%
Net Profit Margin	2.39%	↓ 5.36%

	FY23	Y/Y Change
Revenue	675.0M	↑ 1.22%
Net Income	42.0M	↑ 163.72%
Net Profit Margin	6.22%	↑ 3.83%

	Q1 FY23	Q/Q Change
Revenue	160.3M	↓ 6.75%
Net Income	-19.5M	↑ 93.39%
Net Profit Margin	-12.18%	↓ 6.31%

	Q2 FY23	Q/Q Change
Revenue	169.5M	↑ 5.69%
Net Income	25.8M	↓ 231.87%
Net Profit Margin	15.2%	↑ 27.38%

	Q3 FY23	Q/Q Change
Revenue	163.9M	↓ 3.27%
Net Income	10.9M	↓ 57.85%
Net Profit Margin	6.62%	↓ 8.58%

	Q4 FY23	Q/Q Change
Revenue	181.2M	↑ 10.56%
Net Income	24.9M	↑ 129.05%
Net Profit Margin	13.72%	↑ 7.1%

	Q1 FY24	Q/Q Change
Revenue	167.1M	↓ 7.79%
Net Income	9.0M	↓ 63.9%
Net Profit Margin	5.37%	↓ 8.35%

	Q2 FY24	Q/Q Change
Revenue	178.0M	↑ 6.53%
Net Income	18.9M	↑ 110.34%
Net Profit Margin	10.61%	↑ 5.24%

	FY18	Y/Y Change
Total Assets	689.4M	↑ 9.7%
Total Liabilities	368.1M	↑ 5.51%

	FY19	Y/Y Change
Total Assets	831.1M	↑ 20.56%
Total Liabilities	476.1M	↑ 29.34%

	FY20	Y/Y Change
Total Assets	1.3B	↑ 53.36%
Total Liabilities	654.8M	↑ 37.53%

	FY21	Y/Y Change
Total Assets	2.1B	↑ 62.83%
Total Liabilities	1.3B	↑ 105.39%

	FY22	Y/Y Change
Total Assets	1.7B	↓ 18.99%
Total Liabilities	906.2M	↓ 32.62%

	FY23	Y/Y Change
Total Assets	1.6B	↓ 6.35%
Total Liabilities	704.3M	↓ 22.28%

	Q1 FY23	Q/Q Change
Total Assets	1.5B	↓ 9.39%
Total Liabilities	755.4M	↓ 16.64%

	Q2 FY23	Q/Q Change
Total Assets	1.5B	↑ 1.24%
Total Liabilities	734.4M	↓ 2.78%

	Q3 FY23	Q/Q Change
Total Assets	1.5B	↓ 0.51%
Total Liabilities	702.9M	↓ 4.29%

	Q4 FY23	Q/Q Change
Total Assets	1.6B	↑ 2.6%
Total Liabilities	704.3M	↑ 0.19%

	Q1 FY24	Q/Q Change
Total Assets	1.6B	↑ 0.57%
Total Liabilities	691.2M	↓ 1.86%

	Q2 FY24	Q/Q Change
Total Assets	1.6B	↑ 4.01%
Total Liabilities	767.5M	↑ 11.05%

	FY18	Y/Y Change
Operating Cash Flow	48.9M	↑ 174.78%
Investing Cash Flow	20.6M	↓ 109.2%
Financing Cash Flow	9.0M	↓ 96.01%

	FY19	Y/Y Change
Operating Cash Flow	70.5M	↑ 44.3%
Investing Cash Flow	-128.5M	↓ 724.46%
Financing Cash Flow	3.7M	↓ 59.01%

	FY20	Y/Y Change
Operating Cash Flow	77.0M	↑ 9.23%
Investing Cash Flow	-277.6M	↑ 116.06%
Financing Cash Flow	222.3M	↑ 5957.33%

	FY21	Y/Y Change
Operating Cash Flow	125.7M	↑ 63.2%
Investing Cash Flow	-20.8M	↓ 92.51%
Financing Cash Flow	380.7M	↑ 71.25%

	FY22	Y/Y Change
Operating Cash Flow	145.3M	↑ 15.56%
Investing Cash Flow	-225.2M	↑ 983.14%
Financing Cash Flow	-401.5M	↓ 205.47%

	Q1 FY23	Q/Q Change
Operating Cash Flow	19.1M	↓ 54.5%
Investing Cash Flow	66.2M	↑ 491.5%
Financing Cash Flow	-153.9M	↑ 163.04%

	Q2 FY23	Q/Q Change
Operating Cash Flow	43.5M	↑ 127.41%
Investing Cash Flow	7.3M	↓ 88.93%
Financing Cash Flow	440.0K	↓ 100.29%

Technicals Summary

Sell

Neutral

Buy

Pacira Pharmaceuticals, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Pacira Pharmaceuticals, Inc.	22.48%	-32.99%	-37.56%	-67.07%	-55.87%
Neurocrine Biosciences Inc.	0.22%	-11.71%	9.36%	13.47%	21.32%
Haleon Plc Spon Ads	-5.08%	20.69%	22.01%	36.17%	36.17%
Zoetis Inc.	-0.16%	32.8%	16.08%	-7.35%	52.85%
Viatris Inc.	2.53%	4.53%	31.84%	-16.06%	-28.03%
Catalent, Inc.	0.9%	7.56%	42.8%	-54.43%	23.98%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Pacira Pharmaceuticals, Inc.	13.05	13.05	-3.83	3.04	0.08	0.04	NA	19.07
Neurocrine Biosciences Inc.	35.55	35.55	0.27	4.54	0.16	0.12	NA	24.87
Haleon Plc Spon Ads	32.52	32.52	1.5	0.39	0.07	0.04	0.02	1.82
Zoetis Inc.	37.9	37.9	2.64	5.83	0.49	0.14	0.01	10.94
Viatris Inc.	224.4	NA	0.07	2.67	-0.03	0.03	0.04	16.36
Catalent, Inc.	211.02	NA	3.02	0.2	-0.25	0.0	NA	19.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Pacira Pharmaceuticals, Inc.	Buy	$806.8M	-55.87%	13.05	9.21%
Neurocrine Biosciences Inc.	Buy	$11.9B	21.32%	35.55	16.0%
Haleon Plc Spon Ads	Buy	$45.6B	36.17%	32.52	9.66%
Zoetis Inc.	Buy	$87.6B	52.85%	37.9	26.29%
Viatris Inc.	Hold	$14.0B	-28.03%	224.4	-4.24%
Catalent, Inc.	Hold	$10.9B	23.98%	211.02	-23.81%

Insights on Pacira Pharmaceuticals, Inc.

Increasing Revenue
Revenue is up for the last 2 quarters, 167.11M → 178.02M (in $), with an average increase of 6.1% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, 8.97M → 18.88M (in $), with an average increase of 52.5% per quarter
Vs CTLT
In the last 1 year, Catalent, Inc. has given 43.0% return, outperforming this stock by 81.7%
Vs NBIX
In the last 3 years, Pacira Pharmaceuticals, Inc. has experienced a drawdown of -67.1%, however Neurocrine Biosciences Inc. resisted the overall trend and outperformed by 12.7%